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Abstract
The human pathogen xenotropic murine leukaemia virus-related virus (XMRV) has been tentatively associated with prostate cancer and
chronic fatigue syndrome. Unfortunately, subsequent studies failed to identify the virus in various clinical settings. To determine whether
XMRV circulates in humans and the relationship with its host, we searched for the virus in 124 human immunodeﬁciency virus-infected
patients who might have been exposed to XMRV, might be prone to infection as a result of progressive immunodeﬁciency, and had not
yet been treated with antiretroviral drugs. Using nested PCR and single-step TaqMan real-time PCR, both designed on the XMRV gag
gene, we could not ﬁnd any positive samples. These ﬁndings add to the growing amount of scepticism regarding XMRV.
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Introduction
Xenotropic murine leukaemia virus-related virus (XMRV) is a
novel gamma retrovirus of humans that was ﬁrst discovered
in 2006 [1]. Originally, the virus was isolated from biopsy
specimens of prostate cancer patients, and was believed to
play an aetiological role in that disease; however, subsequent
studies failed to reveal the presence of XMRV in large num-
bers of patients with prostate cancer, possibly because of
uneven geographical distribution of the infection and/or dif-
ferences in the sensitivity of the PCR methods used for
detection [2–8]. In the past 4 years, several reports have
documented the presence of XMRV in blood and respiratory
secretions of subjects with chronic fatigue syndrome, adults
with respiratory illness and transplant patients at rates rang-
ing from 2% to 86%, suggesting that the virus is associated
with various human diseases or is an endogenous virus that
may take advantage of chronic inﬂammation processes or
other underlying diseases (Table 1) [9–17]. To date, how-
ever, the aetiological role of XMRV, if any, is far from being
proven. Moreover, the ﬁnding that tissues and biological ﬂu-
ids of healthy subjects also carry XMRV has led to scepticism
regarding the real pathogenicity of the virus [5,6,9–
11,13,15,16,18].
Many aspects of the natural history and pathogenesis of
XMRV are still poorly understood [19]. These include the
prevalence in the general population and in categories of
subjects who may have greater chances of acquiring XMRV
infection, and the relationship that the virus establishes with
the infected host. Among these individuals, those with human
immunodeﬁciency virus (HIV) infection are particularly at
risk, as they have most likely been exposed to other infec-
tious agents, and, if acquired, XMRV could have taken advan-
tage of the progressive immunodeﬁciency in order to
establish a persistent infection in the host.
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TABLE 1. Summary of studies carried out to detect xenotropic murine leukaemia virus-related virus in patients affected by
various diseases and healthy controls; all studies were performed on peripheral blood leukocytes unless otherwise speciﬁed
Disease No. of samples Prevalence (%) Method Ethnicity References
HIV-positive 124 0 Nested PCR and
real-time PCR for gag
Italy Present study
Prostate cancer (biopsies) 800 0 Real-time PCR for gag
for and
immunohistochemistry
for Gag and Env cleavage
products
USA Aloia et al. [2]
86 40 (RNase L QQ)
1.5 (RNase L RQ)
Real-time PCR for gag USA Urisman et al. [1]
74 4 Real-time PCR The Netherlands Verhaegh et al. [8]
589 0 Nested PCR and RT-PCR Germany Hohn et al. [6]
334 6–23 Real-time PCR and
immunohistochemistry
USA Schlaberg et al. [7]
105 1 Nested PCR Germany Fischer et al. [5]
144 22 Nested PCR for env USA Danielson et al. [4]
Chronic fatigue syndrome 39 Gag- and Env-ELISA
assays; nested PCR
Germany Hohn et al. [31]
170 0 Real-time PCR UK Groom et al. [13]
37 86.5 Nested PCR for gag USA Lo et al. [10]
76 0 Real-time PCR assay for
integrase gene and/or a
nested PCR for gag
The Netherlands van Kuppeveld et al. [14]
65 0 Multiplex real-time PCR
and RT-PCR
China Hong et al. [15]
102 0 Western blot, ELISA; gag
and pol nested PCR
USA Switzer et al. [16]
101 75 Mikovits et al. [12]
186 0 Nested PCR UK Erlwein et al. [17]
32 0 Nested PCR assay for gag USA Henrich et al. [29]
101 67 Nested PCR assay for gag USA Lombardi et al. [9]
Multiple sclerosis with
fatigue symptoms
112 0 Gag- and Env-ELISA
assays; nested PCR
Germany Hohn et al. [31]
Autistic spectrum
disorders
230 0 Real-time PCR and
serology
Italy and South Carolina Satterﬁeld et al. [18]
HCV-positive 67 0 PCR for gag or env United Kingdom Barnes et al. [30]
HIV-positive 101 (acute)
133 (chronic)
0 PCR for gag or env Switzerland and Spain Barnes et al. [30]
43 0 Nested PCR assay for gag USA Henrich et al. [29]
199 plasmas
19 PBMCs
50 culture supernatants
0 Nested PCR or RT-PCR
and real-time PCR assays
Cameroon and Uganda Tang et al. [28]
54 (seminal plasma) 0 Nested PCR for gag The Netherlands Cornelissen et al. [27]
Rheumatoid arthritis 97 0 Nested PCR assay for gag USA Henrich et al. [29]
Spondyloarthritis 19 0 Nested PCR for env France Jeziorski et al. [32]
Paediatric haematological,
neurological or
inﬂammatory pathologies
62 0 Nested PCR for env France Jeziorski et al. [32]
Paediatric respiratory
diseases (nasopharyngeal
aspirates)
80 0 Nested PCR for env France Jeziorski et al. [32]
Respiratory tract infection
without underlying
disease
42 (sputum, nasal swab) 2.3 Nested PCR or real-time
PCR
Germany Fischer et al. [11]
Respiratory tract infection
without underlying
COPD
31 (BAL) 3.2 Nested PCR or real-time
PCR
Germany Fischer et al. [11]
Haematopoietic stem cell
or solid organ transplant
161 (BAL, TS) 9.9 Nested PCR or real-time
PCR
Germany Fischer et al. [11]
26 0 Nested PCR assay for gag USA Henrich et al. [29]
Patients presenting for
medical care
95 0 Nested PCR assay for gag USA Henrich et al. [29]
Healthy controls 40 0 gag- and env-ELISA assays;
nested PCR
Germany Hohn et al. [31]
70 (prostate biopsy) 1.3 Nested RT-PCR Germany Fischer et al. [5]
62 (BAL, throat swab) 3.2 Nested PCR or real-time
PCR
Germany Fischer et al. [11]
97 0 Western blot, ELISA; gag
and pol nested PCR
USA Switzer et al. [16]
44 6.8 Nested PCR for gag USA Lo et al. [10]
218 3.7 Nested PCR for gag USA Lombardi et al. [9]
395 0 Quantitative PCR UK Groom et al. [13]
204 0 Real-time PCR and
serology
Italy and USA Satterﬁeld et al. [18]
65 0 Multiplex real-time PCR
and RT-PCR
China Hong et al. [15]
BAL; bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; PBMC, peripheral blood mononu-
clear cell; QQ, R462Q-homozygous; RQ, R462Q- heterozygous; TS, tracheal secretion.
CMI Maggi et al. XMRV DNA is undetectable in HIV-positive peripheral cells 185
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 184–188
We studied a cohort of 124 HIV-positive patients who
had never received antiretroviral therapy. The presence of
XMRV infection in peripheral blood was investigated by using
two independent molecular methods. Furthermore, in light
of the conﬂicting evidence on the appropriateness of investi-
gated cohorts and methods used to look for the virus, we
reviewed previous studies showing the advantages and
disadvantages of the methodology used.
Materials and Methods
Patients and samples
The study group consisted of 124 randomly selected patients
(97 males and 27 females; mean age 47 ± 14 years; range 18–
80 years). All of them were HIV-seropositive as assessed by
commercial immunoenzymatic and immunoblotting assays, and
HIV-viraemic as assessed by commercial molecular assays. All
patients were treatment-naive. After informed consent had
been obtained, peripheral blood was sampled in EDTA tubes
from each patient. CD4+ T-lymphocyte counts in peripheral
blood at the time of sampling were recorded for each patient.
Aliquots of whole blood and plasma were immediately pre-
pared, stored at )80C, and kept frozen until use.
XMRV PCR
XMRV infection was assessed by extracting DNA from 400 lL
of whole blood with the Maxwell 16 System, according to the
manufacturer’s instructions (Promega, Madison, WI, USA),
using 500–750 ng of DNA as PCR template. The presence of
virus was determined by using the protocol described in part
by Lombardi [9]. This includes a nested PCR and single-step
TaqMan real-time PCR, both designed on XMRV gag. In the
nested PCR, a 413-bp fragment was ampliﬁed in the ﬁrst PCR.
This was carried out for 35 cycles with sense primer GAG-O-F
(5¢-CGCGTTCGATTTGTTTTGTT-3¢) and antisense primer
GAG-O-R (5¢-CCGCCTCTTCTTCATTGTTC-3¢), under the
following conditions: melting at 94C for 30 s, annealing at
52C for 30 s, and extension at 72C for 45 s. The product
of this reaction was then reampliﬁed for 35 cycles with inter-
nal primers GAG-I-F (5¢-TCTCGAGATCATGGGACAGA-3¢)
and GAG-1-R (5¢-AGAGGGTAAGGGCAGGGTAA-3¢)
under the same PCR conditions except for 54C for anneal-
ing. The reactions were carried out in a 50-lL PCR mixture
containing Taq DNA polymerase, each dNTP at a concentra-
tion of 12.5 mM, primers (20 pmol/lL each), and optimized
buffer components. All samples were tested at least in dupli-
cate and on different occasions. The ampliﬁed product was
analysed by electrophoresis on an agarose gel after ethidium
bromide staining. Amplicon size was compared with standard
molecular size markers. XMRV presence was also evaluated
by a single-step TaqMan real-time PCR, designed on a 83-
nucleotide fragment of gag and recently developed in our
laboratory. Brieﬂy, the assay was performed in a 25-lL for-
mat containing 0.9 lM each primer (Q445T, 5¢-GGACTTTT
TGGAGTGGCTTTGTT-3¢; Q528R, 5¢-GCGTAAAACC
GAAAGCAAAAAT-3¢), 0.1 lM labelled probe (F480PRO:
FAM-ACAGAGACACTTCCCGCCCCCG-BHQ), 5 lL of
extracted viral DNA, and a Master Mix containing dNTPs
and Taq DNA polymerase. The reaction was run in triplicate
for each sample in a iQCYCLER real-time PCR detection
instrument (Bio-Rad Laboratories, Hercules, CA, USA), with
a previously standardized program (95C for 10 min;
55 cycles of 95C for 15 s, and 60C for 60 s). PCR data
were collected and analysed with the iQ5 optical system
software, version 2.1, developed by Bio-Rad. To exclude
carryover contamination, negative controls were added dur-
ing the DNA extraction and PCR ampliﬁcation steps. To vali-
date the ampliﬁcation process, positive controls obtained
from supernatants of a constitutively XMRV-infected B-cell
line were run in each PCR. The assay sensitivities were mea-
sured by testing quadruplicates of ten-fold dilutions of the
XMRV-positive control. The real-time PCR was found to have
a sensitivity (about 100 DNA copies per millilitre of whole
blood) of at least a dilution higher than that of nested PCR.
Results
HIV viraemia ranged between 21 and 5 620 000 RNA copies
per millilitre of plasma, with a median of 253 log10, revealing
that plasma HIV load was relatively low in the majority of
patients. The median level of CD4+ T-lymphocytes was
331 cells/lL: 36 (29%) subjects showed CD4+ T-lymphocyte
counts below 200 cells/lL, whereas in 28 patients, the abso-
lute numbers of CD4+ T-lymphocytes were within normal val-
ues for people of the same age (e.g. 500–1500 cells/lL).
XMRV infection was ﬁrst examined by nested PCR. No patient
had detectable viral DNA in the blood (Table 1). As the sensi-
tivity of nested PCR is lower than that of real-time PCR, which
became available after the study commenced, all patients were
retested with the latter method. Again, no evidence of XMRV
DNA could be found, suggesting that this novel retrovirus was
not present in whole blood of study patients.
Discussion
The existence and clinical signiﬁcance of XMRV is still
disputed [19]. Although the virus was initially isolated from
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patients with prostate cancer and CFS, subsequent ﬁndings
have failed to unequivocally link XMRV to these diseases. To
further complicate this picture, it has been recently suggested
that XMRV detected in patient samples is probably the result
of PCR contamination with mouse DNA, and that the tumour
cell line 22Rv1, from which the original XMRV clone was iso-
lated and characterized, was probably infected by murine
XMRV during xenografting in mice [20,21]. Supporting this
idea is the very high similarity between XMRV and its murine
counterpart. As compared with the latter, however, XMRV
has a 24-bp deletion within the gag leader sequence [22],
which is the genomic region targeted by most molecular
methods developed to detect the XMRV genome. This leaves
room for alternative hypotheses [23]. Supporting the exoge-
nous origin is the observation that a few human tissues do
not to express the human innate antiviral resistance factor
APOBEC3G, and may thus create favourable conditions for
XMRV replication and dissemination in the host [24]. These
facts and the lack of identiﬁcation of XMRV or XMRV-related
sequences in the overwhelming majority of studies published
so far (Table 1) strengthen the hypothesis that XMRV is a
zoonosis rather than a genuine human pathogen. Whatever
the origin, it is necessary to determine cell types and organs
that support viral replication and persistence in order to
deﬁne the clinical signiﬁcance of XMRV in humans. Although
the prevalence of XMRV infection has been extensively inves-
tigated in various clinical settings, deﬁnition of target tissue(s)
is far from being completed. In this study, the presence of
XMRV DNA in peripheral blood samples of 124 patients with
HIV infection was investigated with two molecular assays. All
blood samples were XMRV DNA-negative, indicating that the
virus is either absent from the peripheral circulating cells of
HIV-infected individuals or is very rare. Although the pres-
ence of XMRV at levels below our detection threshold cannot
be ruled out, this is very unlikely, as all samples were tested in
duplicate or triplicate with two highly sensitive ampliﬁcation
methods (i.e. nested PCR and real-time PCR), both designed
on the basis of highly conserved fragments of the viral gen-
ome. Moreover, none of the patients was treated with anti-
retroviral drugs such as azidothymidine, tenofovir, and
raltegravir, which are known to inhibit XMRV replication and
hinder detection of the virus [25,26]. In line with our ﬁndings,
recent studies showed no evidence of XMRV in HIV-infected
patients [27–30]. Thus, the major conclusion of our study is
that either HIV infection (and inherent circumstances that
exposed individuals to this and other viruses) does not
increase the risk of acquiring XMRV infection, or that XMRV
does not replicate or persist in peripheral blood cells of HIV
patients and does not inﬂuence CD4+ T-lymphocyte counts in
HIV-positive patients.
Given the long list of studies reporting no occurrence of
the XMRV genome in peripheral blood cells (summarized in
Table 1), it is unlikely that the virus may persist and replicate
in this body compartment. However, the possibility cannot
be excluded that XMRV infection causes sporadic local out-
breaks and its presence could therefore be restricted to
patients with an HIV-unrelated and still unidentiﬁed risk fac-
tor. Further investigations on different populations and larger
number of samples, by using improved PCR assays targeted
to different regions of XMRV genome and directed to detect
viral and proviral forms of the virus, are needed to deter-
mine the real prevalence and distribution of this novel agent.
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